TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26552755

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 2513

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 2513

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2513
Study: 25498565

Group type: EXPERIMENTAL
Intervention: More rigorous dose calculation algorithm (DCA)
Number of subjects: 754

Group type: COMPARATOR
Intervention: Laxative as a method of bowel preparation
Number of subjects: 754
Study: 21386036

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg/5 mg and Ezetimibe
Number of subjects: 78
Study: 20423469

Group type: EXPERIMENTAL
Intervention: Dietetic counselling (by regular home visits and telephone calls) and oral nutritional supplementation for three months after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual dietetic care as provided by the hospital
Number of subjects: 0
Study: 18535196

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 635
Study: 15744633

Group type: EXPERIMENTAL
Intervention: Alcohol withdrawal patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 40
Study: 12587819

Group type: EXPERIMENTAL
Intervention: Low dose i.v. cyclophosphamide (200‐400 mg per month) and prednisone (mean dose 20.5 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisone (mean dose 20.5 mg per day) only or with antimalarials
Number of subjects: 60
Study: 11099587

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) dexamethasone (0.6 mg/kg, maximum 8 mg)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Oral (PO) dexamethasone (0.6 mg/kg, maximum 8 mg)
Number of subjects: 277
Study: 9074572

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Captopril (50 mg three times daily)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 722
Study: 8339536

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 318
Study: 3532694

Group type: EXPERIMENTAL
Intervention: i.v. diazoxide (75-150 mg bolus injections)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: i.m. dihydralazine (6-12.5 mg bolus injections)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Initial treatment with furosemide i.v.
Number of subjects: 64
Study: 28637143

Group type: EXPERIMENTAL
Intervention: Activity monitor during grocery shelving
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Activity monitor during floor sweeping
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Activity monitor during crank ergometer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Activity monitor during table dusting
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Activity monitor during typing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hypothesis testing of group equivalence
Number of subjects: 32
Study: 27236074

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 60
Study: 24735420

Group type: EXPERIMENTAL
Intervention: Internet-based self-help with individual support by a psychologist
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Internet-based self-help with therapist-guided group support
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 150
Study: 24413436

Group type: EXPERIMENTAL
Intervention: Fluid restriction (FR) - 10% of control intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) - 25% of control intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluid and energy restriction (F+ER) - 25% of control energy and 10% of control water intake
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (C) - Adequate energy and water intake
Number of subjects: 12
Study: 21227004

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 108
Study: 19008006

Group type: EXPERIMENTAL
Intervention: One-leg cycling aerobic training program (21 min, alternating 3 min at 70% and 3 min at 85% of VO(2 peak), 15 sessions over 5 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional rehabilitation (5 weeks without cardiorespiratory training)
Number of subjects: 24
Study: 16378639

Group type: EXPERIMENTAL
Intervention: Wavefront-guided Zyoptix Ablation Refinement software (ZAR) LASIK
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Planoscan LASIK
Number of subjects: 20
Study: 14694208

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TRANS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 19
Study: 11314240

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol 50 micrograms/g/ml solution
Number of subjects: 42

Group type: COMPARATOR
Intervention: Betamethasone valerate 1% lotion
Number of subjects: 42
Study: 9007116

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-hour infusion of paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-hour infusion of paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide/cisplatin regimen
Number of subjects: 0
Study: 30262136

Group type: EXPERIMENTAL
Intervention: BEVZ92
Number of subjects: 142

Group type: COMPARATOR
Intervention: Reference bevacizumab
Number of subjects: 142
Study: 26953895

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 343
Study: 24684662

Group type: EXPERIMENTAL
Intervention: Home-based self-help psychoeducation programme
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no participation in the programme)
Number of subjects: 128
Study: 23436922

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 53

Group type: COMPARATOR
Intervention: AZT/3TC
Number of subjects: 53
Study: 20595411

Group type: EXPERIMENTAL
Intervention: STAIR/Exposure
Number of subjects: 104

Group type: COMPARATOR
Intervention: Support/Exposure
Number of subjects: 104

Group type: COMPARATOR
Intervention: STAIR/Support
Number of subjects: 104
Study: 18042657

Group type: EXPERIMENTAL
Intervention: External focus of attention during motor skill practice
Number of subjects: 66

Group type: COMPARATOR
Intervention: Internal focus of attention during motor skill practice
Number of subjects: 66
Study: 16381626

Group type: EXPERIMENTAL
Intervention: Every-3-week therapy (200 mg/m2 paclitaxel, AUC 6 mg/mL/min carboplatin, trastuzumab initial 8 mg/kg, subsequent 6 mg/kg every 21 days for 8 cycles)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Weekly therapy (80 mg/m2 paclitaxel, AUC 2 mg/mL/min carboplatin, trastuzumab initial 4 mg/kg, subsequent 2 mg/kg every 4 weeks for 6 cycles)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Weekly therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Every-3-week therapy
Number of subjects: 91
Study: 12108800

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Attention-Support Control (AS-Control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (CBT and AS-Control)
Number of subjects: 12
Study: 10428124

Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg every 12 hours)
Number of subjects: 3011

Group type: COMPARATOR
Intervention: Warfarin (adjusted-dose)
Number of subjects: 3011
Study: 7555502

Group type: EXPERIMENTAL
Intervention: Diet and exercise (walking at least 10,000 steps/day, monitored by pedometer)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diet alone (normal daily routine, 4,500 +/- 290 steps/day)
Number of subjects: 24
Study: 2372083

Group type: EXPERIMENTAL
Intervention: Prophylactic knee brace
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Control (no knee brace)
Number of subjects: 1396
Study: 6158861

Group type: EXPERIMENTAL
Intervention: dextran 40 (Rheomacrodex)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: plasmanate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (routine treatment with sedatives, bed rest, and magnesium sulfate)
Number of subjects: 32
Study: 31072214

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 33
Study: 27593801

Group type: EXPERIMENTAL
Intervention: Neuronavigation-assisted aspiration and electro-acupuncture (NAEA)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Neuronavigation-assisted aspiration (NA)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conservative therapy (Control)
Number of subjects: 240
Study: 26465152

Group type: EXPERIMENTAL
Intervention: CNI withdrawal after six months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Tacrolimus/sirolimus
Number of subjects: 180

Group type: COMPARATOR
Intervention: Mycophenolate mofetil/sirolimus
Number of subjects: 180
Study: 24266796

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 24
Study: 21864907

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) formulation, 600 mg single dose
Number of subjects: 48

Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation, 300 mg single dose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) formulation, 600 mg q12h multiple doses
Number of subjects: 48

Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation, 300 mg q6h multiple doses
Number of subjects: 48
Study: 19702486

Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.8 mg/kg per day
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5 mg/kg per day, 1.2 mg/kg per day, 1.8 mg/kg per day)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 16900287

Group type: EXPERIMENTAL
Intervention: Coronary Revascularisation Outcome Questionnaire (CROQ)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Seattle Angina Questionnaire (SAQ)
Number of subjects: 199

Group type: COMPARATOR
Intervention: SF‐36
Number of subjects: 199
Study: 15627870

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (9 microg) twice a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral montelukast (10 microg) once a day
Number of subjects: 40
Study: 11840750

Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic foldable lens implantation
Number of subjects: 190

Group type: COMPARATOR
Intervention: PMMA intraocular lens (IOL) implantation
Number of subjects: 190
Study: 9412655

Group type: COMPARATOR
Intervention: Cyclophosphamide 100 mg/m2, Methotrexate 40 mg/m2, 5-Fluorouracil 600 mg/m2 (CMF)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Epidoxorubicin 75 mg/m2 and Vincristine 0.75 mg/m2 (EV)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mitomycin-C 10 mg/m2 and Vindesine 2 mg/m2 (MVs)
Number of subjects: 107
Study: 8276739

Group type: EXPERIMENTAL
Intervention: Clomipramine at top doses of 150 mg/day for 3 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3690230

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) induced hypotensive anaesthesia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no SNP)
Number of subjects: 18
Study: 30312327

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 28780551

Group type: EXPERIMENTAL
Intervention: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention including webinar training, educational resources, free oral nicotine replacement therapy (NRT), and audit and feedback.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 6
Study: 26121878

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 µg Qd
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ipratropium 40 µg Qid
Number of subjects: 220
Study: 23926588

Group type: EXPERIMENTAL
Intervention: Way Milano implants
Number of subjects: 64

Group type: COMPARATOR
Intervention: Kentron implants
Number of subjects: 64
Study: 21397868

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pharmacotherapy (PCT)
Number of subjects: 30
Study: 18358928

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with FOLFOX4 (6 cycles before and 6 cycles after surgery)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with FOLFOX4
Number of subjects: 364
Study: 15737450

Group type: EXPERIMENTAL
Intervention: Quasi‐continuous lengthening (1440 steps per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Step lengthening (twice a day)
Number of subjects: 20
Study: 12534148

Group type: EXPERIMENTAL
Intervention: EGFR inhibitory agents
Number of subjects: 0
Study: 10358689

Group type: EXPERIMENTAL
Intervention: Breast cancer risk counseling intervention
Number of subjects: 508

Group type: COMPARATOR
Intervention: General health education control intervention
Number of subjects: 508
Study: 7863991

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (amiodarone and sotalol)
Number of subjects: 1200
Study: 1778484

Group type: EXPERIMENTAL
Intervention: Health promotion programs participation
Number of subjects: 0
Study: 6120346

Group type: EXPERIMENTAL
Intervention: Slow Sodium (Ciba)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31957521

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 412
Study: 30471012

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks (Q2W)
Number of subjects: 1849

Group type: COMPARATOR
Intervention: Ustekinumab (45 mg for patients ≤ 100 kg; 90 mg for patients > 100 kg)
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg Q2W
Number of subjects: 1849
Study: 30325777

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment interruption (ATI)
Number of subjects: 10
Study: 27907921

Group type: EXPERIMENTAL
Intervention: DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 on day 1, and 5‐fluorouracil 700 mg/m2 for 5 days) every 3 weeks
Number of subjects: 162

Group type: COMPARATOR
Intervention: ACF (adriamycin 35 mg/m2, cisplatin 70 mg/m2 on day 1, and 5‐FU 700 mg/m2 for 7 days) every 4 weeks
Number of subjects: 162
Study: 26219281

Group type: EXPERIMENTAL
Intervention: Individually tailored lifestyle intervention
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study: 23114369

Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 vaccine (20 µg, 60 µg, 200 µg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Twinrix (active control)
Number of subjects: 127
Study: 21861128

Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg orally daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irinotecan 350 mg/m2 intravenously every 3 weeks
Number of subjects: 0
Study: 18752983

Group type: EXPERIMENTAL
Intervention: Cervical lateral glide mobilizations
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17004124

Group type: EXPERIMENTAL
Intervention: High-dose pegylated interferon alpha-2b plus ribavirin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Low-dose pegylated interferon alpha-2b plus ribavirin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 152
Study: 15266728

Group type: EXPERIMENTAL
Intervention: Pharmaceutical company advertisements
Number of subjects: 44

Group type: COMPARATOR
Intervention: Scientific information about depression and its treatment
Number of subjects: 44
Study: 11350400

Group type: EXPERIMENTAL
Intervention: Symptomatic bladder (P2X1/calponin ratio)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Symptomatic bladder (P2X4, P2X5, P2X7 expression)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control bladder (P2X expression levels)
Number of subjects: 9
Study: 9212966

Group type: EXPERIMENTAL
Intervention: Heparin-bonded partial cardiopulmonary bypass with nafamostat mesilate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional partial cardiopulmonary bypass
Number of subjects: 23
Study: 8428872

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) at daily doses averaging 4 to 5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 0
Study: 3619742

Group type: EXPERIMENTAL
Intervention: Panretinal laser photocoagulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diabetic patients (general)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 30-Hz flicker (in diabetic patients)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 72
Study: 28921839

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 79
Study: 27074775

Group type: EXPERIMENTAL
Intervention: QRS duration >120 milliseconds in AF
Number of subjects: 5436

Group type: EXPERIMENTAL
Intervention: QRS duration >120 milliseconds in sinus rhythm
Number of subjects: 5436

Group type: EXPERIMENTAL
Intervention: Increased PR interval (>200 milliseconds)
Number of subjects: 5436
Study: 24948414

Group type: EXPERIMENTAL
Intervention: 5% NaHCO3 solution at 45‐50°C
Number of subjects: 120

Group type: COMPARATOR
Intervention: Talcum powder
Number of subjects: 120
Study: 23710789

Group type: EXPERIMENTAL
Intervention: Single interrupted sutures
Number of subjects: 89

Group type: COMPARATOR
Intervention: Donati sutures
Number of subjects: 89
Study: 19717156

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18400702

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (10% fat; 75% carbohydrates)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Higher fat diet (40% fat; 45% carbohydrates)
Number of subjects: 8
Study: 17427429

Group type: EXPERIMENTAL
Intervention: Soya-based food
Number of subjects: 0
Study: 14607965

Group type: EXPERIMENTAL
Intervention: Dengue virus infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderately ill children with dengue fever
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children who subsequently developed dengue hemorrhagic fever
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls and mild other nondengue febrile illness
Number of subjects: 0
Study: 11004053

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (60 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intravenous nimodipine (30 microg x kg(‐1) x h(‐1) over 20 h)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (initial dose of 30 mg/kg followed by 10 mg x kg(‐1) x h(‐1) over 20 h)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 92
Study: 8945030

Group type: EXPERIMENTAL
Intervention: Medtronic Thera DR pacemaker with automatic mode switching (AMS) algorithm
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Medtronic Thera DR pacemaker with AMS
Number of subjects: 26
Study: 1754849

Group type: EXPERIMENTAL
Intervention: Nocloprost 200 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocloprost 100 micrograms three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocloprost 50-100 micrograms
Number of subjects: 0
Study: 503763

Group type: EXPERIMENTAL
Intervention: Familiar music (rock and easy-listening)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Unfamiliar music (rock and easy-listening)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No music
Number of subjects: 35
Study: 31935118

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 capsules, 2.4 g daily for 12 weeks)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Paraffin oil (control group)
Number of subjects: 93
Study: 31605466

Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (GRS)
Number of subjects: 13945
Study: 27538739

Group type: EXPERIMENTAL
Intervention: Incremental technique with conventional flowable composite (Aelite Flo)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bulk-filling technique with bulk-fill flowable composite (x-tra base)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison between incremental technique and bulk-filling technique
Number of subjects: 37
Study: 26036592

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC), n=29
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group, n=35
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), n=55
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: TAC/MTX, n=14
Number of subjects: 133
Study: 23994918

Group type: EXPERIMENTAL
Intervention: Cytoflavin (20‐40 ml daily intravenously in drops for 10 days)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 191
Study: 22290679

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg (Group D)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg (Group P)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 75
Study: 19803237

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at local points combined with blood‐letting puncture and cupping (on the basis of diet intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of Probenecid (on the basis of diet intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Electroacupuncture plus blood-letting puncture and cupping and Probenecid)
Number of subjects: 60
Study: 16891570

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 12 months
Number of subjects: 13